#United States #Biopharmaceutical #Bridgewater #Insmed Incorporated #NASDAQ INSM

Insmed Achieves Significant Milestone with New Inducement Grants

Insmed Incorporated (Nasdaq: INSM), a leading global biopharmaceutical company dedicated to transforming the lives of patients suffering from serious diseases, recently announced their compliance with NASDAQ Listing Rule 5635(c)(4) through the granting of inducement awards to 150 new employees. This initiative showcases Insmed's commitment to attracting top talent and fostering a culture focused on innovation and patient care.

The grants were issued under the newly established Insmed Incorporated 2025 Inducement Plan, which aims to provide material incentives for new employees as they embark on their journey with the company. These awards were meticulously approved by Insmed's Compensation Committee, reflecting the organization's strategic plans to ensure a competitive edge in the dynamic biopharmaceutical space.

As part of this award process, which commenced on May 30, 2025, the new employees received a total of 155,822 restricted stock units and options that enable them to purchase 16,860 shares of Insmed common stock at a predetermined exercise price of $69.73. This price corresponds to the closing trading price on the Nasdaq Global Select Market on the date the grants were awarded.

Incentive Structure and Vesting Schedule

The restricted stock units come with a vesting schedule spanning four years. Specifically, 25% of the shares will vest on each anniversary of the first day of the month that follows the grant date, contingent on the employees' continued service at Insmed. Such a structure aligns the interests of the employees with those of the shareholders, fostering a long-term vision of collaboration and success.

Additionally, the stock options are set within a 10-year term, mirroring the four-year vesting schedule of the restricted stock units. These options will also vest incrementally—with 25% vesting on the first anniversary and 12.5% every six months thereafter until fully vested, again dependent on the employees remaining with Insmed throughout the vesting period.

About Insmed and Its Commitment to Patients

Founded with a mission to deliver first- and best-in-class therapies, Insmed is committed to addressing the challenges faced by patients with serious diseases. Their extensive portfolio includes approved medications and those under various stages of investigation, particularly focusing on pulmonary and inflammatory conditions. One of their flagship therapies has gained approval in major markets including the United States, Europe, and Japan, aimed at treating chronic debilitating lung diseases.

Moreover, Insmed is at the forefront of innovative drug discovery initiatives, exploring diverse technologies ranging from gene therapy to AI-driven protein engineering and synthetic rescue methods. Their dedication ensures that they are not only meeting current patient needs but are also preparing for future healthcare challenges.

Acknowledgement of Excellence

Insmed's persistent efforts have led to its recognition as one of the foremost employers in the biopharmaceutical sector, consistently earning accolades, including the prestigious title of No. 1 Science Top Employer for four consecutive years. This recognition underscores the company's focus on workplace quality, professional development, and employee satisfaction.

For more information on Insmed's growth, career opportunities, and innovative therapies, visit their official website at www.insmed.com.

Conclusion

In summary, Insmed's recent inducement awards not only comply with NASDAQ regulations but also solidify its position as a frontrunner in attracting talent crucial for the advancement of critical therapies. By investing in its workforce, Insmed is ultimately working to achieve its overarching goal of making a transformative impact on the lives of patients across the globe.